HSCI Executive Committee member Lee Rubin is one of seven scientists selected by biotech leader Biogen Idec to identify and develop new approaches for treating amyotrophic lateral sclerosis (ALS) - more commonly known as Lou Gehrig's disease. Rubin and the other six scientists at Harvard, Yale, Columbia, and Rockefeller will form a consortium to bring to bear their complementary research interests, talents, and areas of expertise on the hitherto untreatable and fatal neurodegenerative disease.

Click here to read more about the plans for the consortium.